The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
The authors prepared and tested press-coated tablets with various weight ratios of ethylcellulose to hydroxypropylcellulose (HPC) and various ratios of two different batches of HPC as an outer coating shell and fillers in core tablets. The tablets were examined for changes in time lag and release patterns of salbutamol sulfate.


Pharmaceutical Technology


Results and discussion

In vitro dissolution study of core tablets. Figure 1 and Figure 2 show the release profiles of salbutamol sulfate from the uncoated tablets prepared with Starlac and Avicel PH 101 as a filler, respectively. Upon contact with the dissolution medium, core tablets prepared using Starlac as a filler started to erode and released the drug. Starlac is a coprocessed excipient consisting of lactose monohydrate and maize starch (85:15) (10). As a result of both hydration and disintegrant properties of Starlac, upon contact with the dissolution medium, this core tablet erodes and provides release within 12 min. No significant effect from Ac-Di-Sol was observed on the release pattern of the drug. Core tablets prepared with Avicel PH 101 as a filler, upon contact with the dissolution medium tablets, swelled, disintegrated, and released the drug. As the amount of Ac-Di-Sol increased, the drug release increased. Figure 3 shows the release pattern of albutamol sulfate from the uncoated tablets prepared using Starlac and Avicel PH 101 as a filler.


Figure 1

Figure 2












Figure 3
In vitro dissolution study of press-coated tablets. Rupturable polymer (EC) combined with erodible polymer (HPC EXF). As shown by Figure 4 and Figure 5, when rupturable polymer (EC N 22 F) combined with erodible polymer (HPC EXF), lag time increased with an increasing weight ratio of EC N 22 F to HPC EXF. Using EC N 22 F alone resulted in the shortest lag time compared to any weight ratio of EC N 22 F to HPC EXF. This occurs because EC is semipermeable in nature and, although it is naturally insoluble in the dissolution medium, it penetrates the coating layer of the tablet when used alone. After hydration of the core, the drug was released.


Figure 4
For tablets in which EC was used with HPC EXF, and as a result of the solubility of HPC EXF, upon contact with the dissolution medium, HPC EXF hydrated and formed a compact with EC. In addition, the hydrophobicity of EC retards the hydration of HPC EXF. Therefore, the dissolution medium did not penetrate the outer-coating layer but the coating eroded slowly.


ADVERTISEMENT

RELATED CONTENT
Roche Recalls Viracept
Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
Near-Infrared Assay and Content Uniformity of Tablets
Maintain Your Moving Parts
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here